Asset Details
Do you wish to reserve the book?
Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study
Do you wish to request the book?
Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study
2025
Overview
Aim
Sepsis-induced cardiomyopathy (SICM) is a transient cardiac dysfunction that occurs in a substantial proportion of patients with sepsis and is associated with poor prognosis. However, preventive strategies remain limited. This study aimed to assess whether baseline use of sodium-glucose co-transporter 2 inhibitors (SGLT2is) compared to dipeptidyl peptidase-4 inhibitors (DPP4is) is associated with a reduced risk of SICM in patients with type 2 diabetes mellitus (T2D) and sepsis.
Methods
Using the TriNetX global health research network, we conducted a retrospective cohort study including adult patients with T2D and infection who were prescribed either SGLT2is or DPP4is within three months before infection. Propensity score matching (PSM) was applied to balance baseline characteristics. The primary outcome was SICM within 30 days; secondary outcomes included 1-year all-cause mortality, hospitalization, and major adverse cardiovascular events (MACEs).
Results
After 1:1 PSM for demographics, comorbidities, and medications, 73,069 patients were included in each group. SGLT2is use was associated with a significantly lower risk of SICM (hazard ratio [HR], 0.78; 95% CI, 0.71–0.86), all-cause mortality (HR, 0.58; 95% CI, 0.55–0.62), hospitalization (HR, 0.83; 95% CI, 0.79–0.87), and MACEs (HR, 0.86; 95% CI, 0.80–0.93), all
P
< .001, compared to DPP4is therapy. Subgroup analyses and negative control outcomes supported the robustness of the findings.
Conclusions
Among patients with T2D and sepsis, SGLT2is were associated with a lower risk of SICM and improved long-term cardiovascular outcomes, compared to DPP4is therapy. These results support further prospective studies to validate the role of SGLT2is in preventing SICM.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Cardiomyopathies - epidemiology
/ Complications and side effects
/ Diabetes
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - epidemiology
/ Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
/ Edema
/ Female
/ Glucose
/ Humans
/ Male
/ Medicine
/ Patients
/ Sepsis
/ Sodium-Glucose Transporter 2 Inhibitors - adverse effects
